BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...leakage by endothelial cells. Synthekine Therapeutics Inc.’s lead program, STK-012...
BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...Bright Peak Therapeutics Inc. and others (see “Next-Wave Th1 Cytokine Cancer Therapies”). Synthekine’s lead program is STK-012...
Items per page:
1 - 2 of 2